3 New Strong Buy Ratings from Top-Rated Analysts: 04/09/2026
Oh happy day. Here are three fresh Strong Buy ratings to check out:
- AbbVie Inc (ABBV) — Dividend aristocrat with expanding oncology firepower
- Teva Pharmaceutical Industries Ltd (TEVA) — Turnaround play surging 139% with biosimilar momentum
- Calix Inc ($CALX) — AI-powered broadband disruptor with 580% earnings growth
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Wall Street Sees Big Upside in These 5 Stocks Under $10 There's a reason each of these stocks caught our attention. Important developments are already underway, and if they play out favorably, Wall Street may have reason to reconsider what these companies are worth. Our new free report covers 5 stocks trading below $10 that analysts believe could have plenty of room to run. Download Free Report1. Abbvie Inc (NYSE: ABBV)
AbbVie has a problem most companies would envy: replacing a blockbuster drug like Humira — and actually pulling it off. With an expanding oncology lineup, rock-solid dividends, and a strong 2026 forecast, the 3-ranked drug manufacturer is giving investors plenty of reasons to pay attention.
Zen Rating: B (Buy) — see full analysis
Recent Price: $207.70 — get current quote
Max 1-year forecast: $299.00
Why we're watching:
- Analyst support: Right now, 14 analysts we track issue ratings on ABBV. It earns 8 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings, demonstrating solid conviction despite macro uncertainties. See the ratings
- For instance, Piper Sandler's David Amsellem (a top 7% rated analyst) maintains a Strong Buy rating with a $299.00 price target (over 40% upside), remarking on AbbVie's strong fundamentals and growth trajectory, especially in immunology.
- Industry ranking context: ABBV is currently the 5th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A, positioning it among pharmaceutical elite. See more stocks in the industry here.
- Zen Rating highlights: Right now, ABBV ranks in the top 17% of 4,600+ stocks we track and earns an overall grade of B (Buy), which is above average.
- Component Grades: The company shows specific strength in Safety, Growth and Financials — it earns above-average B Component Grades in each of these areas. See all 7 Zen Component Grades here.
2. Teva Pharmaceutical Industries (NYSE: TEVA)
Teva Pharmaceutical Industries is in the middle of a multi-year transformation — and it's starting to pay off. The 3-ranked pharmaceutical company just scored FDA approval for its Prolia biosimilar PONLIMSI™, with a Xolair filing acceptance signaling even more growth ahead as Teva pivots toward higher-value products.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $29.90 — get current quote
Max 1-year forecast: $45.00
Why we're watching:
- Analyst support: TEVA enjoys exceptional Wall Street confidence with 6 Strong Buy ratings and 1 Buy rating out of 7 total analysts, with no Hold or Sell recommendations. See the ratings
- For instance, Piper Sandler's David Amsellem (a top 7% rated analyst) reiterated a Strong Buy rating with a $41.00 price target (suggesting nearly 40% upside) in early March, maintaining conviction in the turnaround story.
- Industry ranking context: TEVA is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B, placing it among top-tier drug manufacturers.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — TEVA is part of this elite tier of the top-rated stocks we track in our 4600+ ticker database.
- Component Grades: The company earns B grades across Value, Growth, Momentum, Safety, and artificial intelligence integration, reflecting balanced strength across multiple dimensions. See all 7 Zen Component Grades here
3. Calix Inc (NYSE: CALX)
Calix Inc is quietly becoming the AI backbone of America's broadband buildout. The #7-ranked app company just launched its AI-native Calix One platform and landed one of the nation's largest BEAD-funded fiber deployments, with up to $1.5 billion in BEAD opportunity ahead and agentic AI solutions already driving record revenue past the $1 billion mark.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $49.95 — get current quote
Max 1-year forecast: $90.00
Why we're watching:
- Analyst support: CALX enjoys 2 Strong Buy ratings and 1 Buy rating out of 3 total analysts — as an added bonus, all three analysts are ranked in the top 1% based on stock-picking performance. See the ratings
- For example, JP Morgan's Samik Chatterjee (a top 1% rated analyst) upgraded CALX to Strong Buy with a $90.00 price target in January 2026, representing a remarkable +86% upside potential from current levels.
- Needham analyst Ryan Koontz (top 1%) maintains a Buy rating with a $70.00 target, noting that while Q1 2026 guidance was mixed due to seasonal winter fiber passing declines, the new agentic workforce cloud platform has "very strong potential" to "revolutionize customers' businesses."
- Industry ranking context: CALX is currently the 7th highest-rated stock in the App industry, which has an Industry Rating of B, positioning it strongly among software and platform providers.
- Zen Rating highlights: CALX earns an overall A (Strong Buy) Zen Rating. This rating is only given to the top 5% of stocks we track based on a detailed 115-factor analysis, and stocks that earn this rating have historically gained over 30% annually.
- Component Grades: The company earns an A in Growth and a B in Financials, while holding C grades in Value, Momentum, Sentiment, Safety, and Artificial Intelligence — reflecting solid growth execution as it scales its AI-native broadband platform. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.